Geneva, Switzerland, July 19, 2018.

Abologix has entered into an exclusive, worldwide in-license agreement with Research Development Foundation for two monoclonal antibodies for oncological indications that were developed at the University of Geneva with funding from Institut Clayton de la Recherche.

During the past 10+ years Institut Clayton de la Recherche has funded research at the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva, mostly in the understanding of the biochemistry of cell adhesion molecules and extracellular matrix-related proteins in leukocyte transmigration and tumor angiogenesis.As a result of this work monoclonal antibodies blocking JAM-C and Olfml3 have been obtained.

They have shown initial promise in the treatment of a wide set of cancer indications.

We are delighted to have the opportunity to continue the development of the programs that have been initiated at the University of Geneva. Antibodies blocking JAM-C and Olfml3 have so far shown impressive potential in animal models of several cancer indications

said Ignacio Faus, co-founder and Chairman of the Board of Abologix.

Geneva, Switzerland, January 25, 2018.

Abologix was launched today, and it is the newest addition to the biotechnology ecosystem in the city of Geneva (Switzerland).

The three founders of Abologix are Dr.Ignacio Faus, Prof. Beat Imhof and Prof. Thomas Matthes.The company intends to develop novel monoclonal antibodies for the treatment of JAM-C positive hematological tumours.New therapeutics for the treatment of difficult to manage solid tumours will de developed by blocking the Olfml3 target.

Dr. Ignacio Faus has been named Chairman of the Board of the company. He has more than 20+ years of experience in the pharmaceutical and biotechnology industries, in companies both in the USA and in Europe.

Abologix is a pre-clinical stage biopharmaceutical company developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein Olfactomedin-like protein 3 (Olfml3) for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Genevaand the Hôpitaux Universitaires de Genève.

Copyright © 2021 ABOLOGIX